Document Detail


Importance of diet in the treatment of familial hypercholesterolemia.
MedLine Citation:
PMID:  8213496     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The principal goal of dietary treatment of heterozygous familial hypercholesterolemia (hFH) is the reduction of the plasma low density lipoprotein (LDL) cholesterol. This is best accomplished by enhancing the activity of LDL receptors and, at the same time, depressing liver synthesis of cholesterol. Both cholesterol and saturated fat down-regulate the LDL receptor and inhibit the removal of LDL from the plasma by the liver. Saturated fat down-regulates the LDL receptor, especially when cholesterol is concurrently present in the diet. The total amount of dietary fat is also important. The greater the flux of chylomicron remnants into the liver, the greater is the influx of cholesterol ester. In addition, factors that affect LDL synthesis could be important. These include excessive calories (obesity) that enhance very low density lipoprotein (VLDL) and, hence, LDL synthesis, and weight loss and omega-3 fatty acids, which depress synthesis of VLDL and LDL. The optimal diet for treatment of children and adults has the following characteristics: cholesterol (100 mg/day), total fat (20% of kcal, 6% saturated with the balance from omega-3 and omega-6 polyunsaturated and monounsaturated fat), carbohydrate (65% kcal, 67% from starch), and protein (15% kcal). This low-fat, high-carbohydrate diet can lower the plasma cholesterol 18-21%. A new concept, the Cholesterol-Saturated Fat Index, allows people to evaluate any foodstuff for its potential to elevate the plasma LDL cholesterol level. It is an antithrombotic diet, thrombosis being another major consideration in preventing coronary heart disease. Also, it contains significant amounts of antioxidants and fiber. Dietary therapy is the mainstay of treatment of hFH to which various drug therapies can be added.
Authors:
W E Connor; S L Connor
Related Documents :
9109446 - Mildly oxidized ldl induces an increased apolipoprotein j/paraoxonase ratio.
11814466 - Gradient gel electrophoretic separation of ldl and hdl subclasses on biorad mini protea...
1558836 - Accumulation of 125i-tyramine cellobiose-labeled low density lipoprotein is greater in ...
11472706 - Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogeni...
2667936 - Probucol. a reappraisal of its pharmacological properties and therapeutic use in hyperc...
8902186 - Gender differences in serum leptin levels in humans.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  72     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1993 Sep 
Date Detail:
Created Date:  1993-10-28     Completed Date:  1993-10-28     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  42D-53D     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, Oregon Health Sciences University, Portland 97201-3098.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cholesterol, Dietary / administration & dosage
Dietary Carbohydrates / administration & dosage
Dietary Fats / administration & dosage*
Humans
Hyperlipoproteinemia Type II / blood,  diet therapy*
Lipids / blood
Grant Support
ID/Acronym/Agency:
DK29930/DK/NIDDK NIH HHS; HL25867/HL/NHLBI NIH HHS; HL37940/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Cholesterol, Dietary; 0/Dietary Carbohydrates; 0/Dietary Fats; 0/Lipids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Who should treat familial hypercholesterolemia?
Next Document:  How effective is drug therapy in heterozygous familial hypercholesterolemia?